Related Experiment Video
Updated: Dec 9, 2025
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.7K
Correction to: Cardiac Contractility Modulation: an Important Therapy in the Treatment of Advanced Heart Failure
Jonathan B Edelson1, Michael V Genuardi2, Pasquale Santangeli2
1Division of Cardiology, Cardiac Center, the Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Edelsonj@email.chop.edu.
Current Cardiology Reports
|September 8, 2020
Insights
The article title has an error. This correction ensures accurate scientific communication and proper indexing of research findings.
Area of Science:
- Scientific communication
- Publication accuracy
Context:
- Ensuring the integrity of scientific literature
- Accurate representation of research findings
Purpose:
- To correct a mistake in the original article title
- To improve the discoverability and citation accuracy of the research
Summary:
- The original publication's title contained an error.
- This correction rectifies the title for clarity and precision.
Impact:
- Improved accuracy in scientific databases
- Enhanced credibility of the published research
- Facilitates correct referencing and citation
Abstract:
The article title in the original publication contains a mistake.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
181
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
181
01:22Heart Failure VI: Adjunct Therapies
149
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
149
01:30Cardiomyopathy II: Dilated Cardiomyopathy
280
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
280
01:30Heart Failure V: Medical Management
125
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
125
01:26Heart Failure Drugs: Inotropic Agents
1.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
737
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
737